OLDWICK, N.J., June 30, 2020 /PRNewswire/ -- Provention
Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to
intercepting and preventing immune-mediated diseases, announced
today a change in the format of its 2020 Annual Meeting of
Stockholders (the "Annual Meeting") from in-person to a
virtual-only meeting format due to the continuing public health
impact of COVID-19 and to support the health and safety of the
Company's stockholders and attendees. As previously announced, the
Annual Meeting will be held on Wednesday,
July 15 at 9:00 a.m. Eastern
Time ("ET").
If you were a stockholder of record at the close of business on
May 22, 2020, the Company's record
date, or you hold a valid proxy for the Annual Meeting, you can
vote at the Annual Meeting at
www.virtualshareholdermeeting.com/PRVB2020.
A summary of the information you need to attend the Annual
Meeting is provided below:
- Instructions on how to attend and participate via the Internet,
including how to demonstrate proof of stock ownership, will be
posted at www.virtualshareholdermeeting.com/PRVB2020;
- Assistance with questions regarding how to attend and
participate via the Internet will be provided at
www.virtualshareholdermeeting.com/PRVB2020 on the day of the Annual
Meeting;
- Stockholders may vote and submit questions on the day of and
while attending the Annual Meeting via the Internet;
- You will need your 16-Digit Control Number (provided to you in
your proxy materials) to enter the Annual Meeting; and
- The proxy materials for the Annual Meeting are available at
www.proxyvote.com.
We encourage you to access the Annual Meeting 10 minutes prior
to the start time. Online check-in will begin at 8:50 a.m. ET. We will have technicians ready to
assist you with any technical difficulties before the virtual
Annual Meeting begins on the day of the Annual Meeting at
www.virtualshareholdermeeting.com/PRVB2020.
About Provention Bio, Inc.
Provention Bio, Inc.
(Nasdaq: PRVB) is a biopharmaceutical company leveraging a
transformational drug development strategy focused on the
prevention or interception of immune-mediated disease. Provention's
mission is to source, transform and develop therapeutic candidates
targeting the high morbidity, mortality and escalating costs of
autoimmune diseases. Provention's diversified portfolio includes
teplizumab, a pre-commercial-stage candidate that has been shown to
delay the onset of insulin-dependent type 1 diabetes (T1D) in
at-risk patients during the presymptomatic phase of the disease.
The Company's portfolio includes additional clinical product
development candidates that have demonstrated proof-of-mechanism
and/or proof-of-concept in other autoimmune diseases, including
celiac disease and lupus.
Investor Contact:
Sam
Martin, Argot Partners
Sam@argotpartners.com
212-600-1902
Media:
Lori
Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-announces-change-to-a-virtual-meeting-format-for-the-2020-annual-meeting-of-the-stockholders-301086290.html
SOURCE Provention Bio, Inc.